LXEO - Lexeo Therapeutics, Inc.
3.25
-1.200 -36.923%
Share volume: 1,751,358
Last Updated: 05-06-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
$4.45
-1.20
-0.27%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-09-2024 | 08-12-2024 | 11-13-2024 | 03-24-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 23.291 M | 23.550 M | 31.543 M | 27.382 M | |
| Selling general and admin | 7.549 M | 6.990 M | 8.120 M | 9.016 M | |
| Research and development | 15.742 M | 16.560 M | 23.423 M | 18.366 M | |
| Total expenses | 23.291 M | 23.550 M | 31.543 M | 27.382 M | |
| 1.11% | 33.94% | -13.19% | |||
| Operating income | -23.291 M | -23.550 M | -31.543 M | -27.382 M | |
| Ebit | -23.296 M | -23.551 M | -31.546 M | -27.382 M | |
| Pretax income | -21.682 M | -21.238 M | -29.489 M | -25.924 M | |
| -2.05% | 38.85% | -12.09% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -21.682 M | -21.238 M | -29.489 M | -25.924 M | |
| 2.05% | -38.85% | 12.09% |
